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Nosocomial infections are also known as hospital-acquired/associated infections. Na-
tional Healthcare Safety Network along with Centers for Disease Control for surveillance
has classiﬁed nosocomial infection sites into 13 types with 50 infection sites, which are
speciﬁc on the basis of biological and clinical criteria. The agents that are usually
involved in hospital-acquired infections include Streptococcus spp., Acinetobacter spp.,
enterococci, Pseudomonas aeruginosa, coagulase-negative staphylococci, Staphylo-
coccus aureus, Bacillus cereus, Legionella and Enterobacteriaceae family members,
namely, Proteus mirablis, Klebsiella pneumonia, Escherichia coli, Serratia marcescens.
Nosocomial pathogens can be transmitted through person to person, environment or
contaminated water and food, infected individuals, contaminated healthcare personnel's
skin or contact via shared items and surfaces. Mainly, multi-drug-resistant nosocomial
organisms include methicillin-resistant Staphylococcus aureus, vancomycin-resistant
enterococci, Pseudomonas aeruginosa and Klebsiella pneumonia, whereas Clostridium
difﬁcile shows natural resistance. Excessive and improper use of broad-spectrum anti-
biotics, especially in healthcare settings, is elevating nosocomial infections, which not
only becomes a big health care problem but also causes great economic and production
loss in the community. Nosocomial infections can be controlled by measuring and
comparing the infection rates within healthcare settings and sticking to the best healthcare
practices. Centers for Disease Control and Prevention provides the methodology for
surveillance of nosocomial infections along with investigation of major outbreaks. By
means of this surveillance, hospitals can devise a strategy comprising of infection control
practices.1. Introduction
“Nosocomial” term is used for any disease acquired by pa-
tient under medical care [1]. It is an infection acquired by patient
during hospital stay. Recently, a new term, “healthcare
associated infections” is used for the type of infections caused
by prolonged hospital stay and it accounts for a major risk
factor for serious health issues leading to death [2]. About 75%
of the burden of these infections is present in developingcountries [3]. Asymptomatic patients may be considered
infected if these pathogens are found in the body ﬂuids or at a
sterile body site, such as blood or cerebrospinal ﬂuid [4].
Infections that are acquired by hospital staff, visitors or other
healthcare personnel may also be considered as nosocomial [5].
The situations in which infections are not believed as noso-
comial are: (1) The infections that were present at the time of
admission and become complicated, nevertheless pathogens or
symptoms change resulting to a new infection; (2) The in-
fections that are acquired trans-placentally due to some diseases
like toxoplasmosis, rubella, syphilis or cytomegalovirus and
appear 48 h after birth [6].
Hospital-acquired infections appeared before the origination
of hospitals and became a health problem during the miraculous
antibiotic era. Due to these infections, not only the costs but alsoicle under the CC BY-NC-ND
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This resulted in elevated morbidity and mortality. Studies con-
ducted in different parts of the world show that in North
America and Europe 5%–10% of all hospitalizations result in
nosocomial infections, while Latin America, Sub-Saharan Africa
and Asia show more than 40% hospitalizations with nosocomial
infections [7].
Nosocomial infections can be caused by any organisms but
few organisms are particularly responsible for hospital-acquired
infections. In this review article, a brief overview on different
aspects of nosocomial infections, particularly sites of infections,
common nosocomial bacterial agents, selected antibiotic-
resistant pathogens along with their modes of transmission and
control measures will be discussed.
2. Types of nosocomial infections
National Healthcare Safety Network with Center for Disease
Control (CDC) for surveillance has classiﬁed nosocomial infec-
tion sites into 13 types, with 50 infection sites, which are speciﬁc
on the basis of biological a nd clinical criteria. The sites which are
common include urinary tract infections (UTI), surgical and soft
tissue infections, gastroenteritis, meningitis and respiratory in-
fections [8]. A change regarding nosocomial infection sites can be
easily detected with time due to the elevated use of cancer
chemotherapy, advancement in organ transplantation,
immunotherapy and invasive techniques for diagnostic and
therapeutic purposes. The perfect example of this can be seen in
the case of pneumonia as prevalence of nosocomial pneumonia
increased from 17% to 30% during ﬁve years [9].
3. Agents of nosocomial infections
Nosocomial infections are caused by many microbes and each
one can cause infection in healthcare settings. Bacteria are
responsible for about ninety percent infections, whereas pro-
tozoans, fungi, viruses and mycobacteria are less contributing
compared to bacterial infections [10]. The agents that are usually
involved in hospital-acquired infections include Streptococcus
spp., Acinetobacter spp., enterococci, Pseudomonas aeruginosa
(P. aeruginosa), coagulase-negative staphylococci, Staphylo-
coccus aureus (S. aureus), Bacillus cereus (B. cereus), Legionella
and Enterobacteriaceae family members including Proteus mira-
blis, Klebsiella pneumonia (K. pneumonia), Escherichia coli
(E. coli), Serratia marcescens. Out of these enterococci,
P. aeruginosa, S. aureus and E. coli have a major role [11]. UTI
usually contain E. coli, while it is uncommon in other infection
sites. Contrarily, S. aureus is frequent at other body sites and
rarely causes UTI. In blood-borne infections, coagulase-negative
S. aureus is the main causative agent. Surgical-site infections
contain Enterococcus spp. which is less prevalent at respiratory
tract. One tenth of all infections are caused by P. aeruginosa,
which is evenly distributed to the entire body sites [4].
Excessive and improper use of broad-spectrum antibiotics,
especially in healthcare settings, are elevating nosocomial in-
fections. Penicillin-resistant pneumococci, multi-drug-resistant
tuberculosis, methicillin-resistant S. aureus (MRSA),
vancomycin-resistant S. aureus are common examples of drug-
resistant bacteria. The distribution of bacteria in nosocomial
infections is changing over time. For example, Proteus spp.,
Klebsiella spp. and Escherichia spp. were responsible fornosocomial infections in the 1960s, but from 1975 to 1980s,
Acinetobacter spp. with P. aeruginosa created clinical difﬁ-
culties [12]. During the recent years, streptococci along with
coagulase-negative staphylococci and coagulase-positive staph-
ylococci reemerged and incidence level of K. pneumonia and
E. coli declined from 7% to 5% and 23%–16%, respectively [13].
4. Bacteriology of commonly isolated nosocomial
pathogens
A multicenter study was conducted in Japan to isolate bac-
teria from surgical infections during 2011–2012. About 785
strains including 31 of Candida spp. were isolated from 204 out
of 259 surgical patients. About 523 strains were isolated from
primary infections and 231 from surgical site infection. From
primary infections, anaerobic Gram-negative bacteria were
prevalent. Enterococcus spp. was the highest among Gram-
positive aerobic bacteria followed by Streptococcus and Staph-
ylococcus spp. E. coli was the predominant form among the
Gram-negative aerobic bacteria followed by K. pneumonia,
P. aeruginosa and Enterobacter cloacae [14].
4.1. S. aureus
Out of many species of Staphylococcus genus, S. aureus is
considered one of the most important pathogens, responsible for
nosocomial infections. It is Gram-positive cocci, non-spore
forming, catalase- and coagulase-positive, immotile, faculta-
tively anaerobe [15]. It is not only a disease-causing organism but
also plays its role as commensal. It mainly colonizes in nasal
passages. About 20% individuals have persistent colonization of
S. aureus, whereas 30% are intermittent. Hospitalized patients
with decreased immunity and immunocompetent people in
community are more prone to S. aureus infections. S. aureus
infects not only the superﬁcial but also the deep tissues and local
abscess lesion. Toxin-mediated diseases of S. aureus include
food poisoning, due to ingestion of enterotoxins, while toxic
shock syndrome toxin 1 is responsible for toxic shock syndrome
[16] and exfoliative toxins cause staphylococcal scalded skin
syndrome. Virulence mechanisms of S. aureus include toxins,
enzymes and immune modulators [15].
4.2. E. coli
E. coli is an emerging nosocomial pathogen causing prob-
lems in health care settings [17]. E. coli is Gram-negative and
oxidase-negative facultative anaerobe bacteria. It can colonize in
gastrointestinal tract of human beings and other animals. E. coli
is responsible for a number of diseases including UTI, septi-
cemia, pneumonia, neonatal meningitis, peritonitis and gastro-
enteritis. Virulence factors meant for its pathogenicity are
endotoxins, capsule, adhesions and type 3 secretion systems [18].
Specialized virulence factors are seen in case of UTI and
gastroenteritis.
4.3. Vancomycin-resistant enterococci
Enterococci is the second leading cause of hospital acquired
infections worldwide and the main leading cause in United
States contributing 20%–30% of infections. These are facultative
anaerobic Gram-positive enteric microbes [19]. They are a part of
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tract as well. Enterococci are involved in the blood-borne in-
fections; UTI and wound infections consort to surgical pro-
cedures [20]. Virulence factors include extracellular surface
proteins, cytolysin, adhesions, hemolysins, gelatinase,
extracellular superoxide and aggregation substances [21].
4.4. K. pneumonia
Three to seven percent of hospital-acquired bacterial in-
fections are related to K. pneumonia, which is the eighth sig-
niﬁcant pathogen in healthcare settings. It is a Gram-positive
bacillus and an opportunistic bacterium, which is a part of
Enterobacteriaceae family. It usually colonizes gastrointestinal
tract, pharynx and skin. It gets involved in diseases such as
neonatal septicaemia, pneumonia, wound infections and septi-
cemia. Its virulence factors include endotoxins, cell wall re-
ceptors and capsular polysaccharide [22].
4.5. P. aeruginosa
P. aeruginosa contributes to 11% of all nosocomial in-
fections, which result in high mortality and morbidity rates. It is
non-fermenter Gram-negative organism causing diseases espe-
cially among immune-compromised people. The sites of colo-
nization are kidney, urinary tract and upper respiratory tract. It is
a cause of surgical and wound infections, UTI, pneumonia,
cystic ﬁbrosis and bacteremia. Some of important virulence
factors are adhesions, hemolysins, exotoxins, proteases and
siderophores [23].
4.6. Clostridium difﬁcile (C. difﬁcile)
C. difﬁcile is an important nosocomial pathogen which
mainly causes diarrhea. Several cases of C. difﬁcile are reported
in Europe, U.S. and Canada. It is a Gram-positive bacillus. It is
anaerobic and spore-forming bacteria. It usually colonizes in
intestinal tract and serves as part of normal microbiota [24].
Diseases caused by toxins produced by C. difﬁcile are colitis
and it is responsible for 15%–25% cases of diarrhea. Major
virulence factors for C. difﬁcile are toxins, ﬁmbriae, capsule
and hydrolytic enzymes [25].
5. Modes of transmission
5.1. S. aureus
Transmission of S. aureus is through infected individuals’
skin or contact via shared items and surfaces like door handles,
benches, towels and taps.
5.2. E. coli
E. coli can be transmitted through person to person, envi-
ronment or contaminated water and food [17].
5.3. Vancomycin-resistant enterococci
Patients with diarrhea are common means of transmission.
Their room items such as surfaces and equipments act as res-
ervoirs. This bacterium can survive on theses surfaces for daysor weeks and become a source of contamination for healthcare
individuals and other patients [21].
5.4. K. pneumonia
In hospital settings, K. pneumonia can be transmitted by
person-to-person contact and especially when healthcare pro-
fessionals do not wash or clean hands after checking a
contaminated patient. Respiratory machines, catheters or
exposed wounds can be the source of its transmission.
K. pneumoniae is reported to be transmitted through stool
(77%), patients’ hands (42%) and pharynx (19%) [22].
5.5. P. aeruginosa
Common reservoirs for its contamination include breast
pumps, incubators [26], sinks and hands of hospital staff and
hand soaps [27].
5.6. C. difﬁcile
Spores of C. difﬁcile can hold for months and become a
problem for disinfectants and cleaning agents. Inanimate objects
and infected intestinal patients are major sites acted as reser-
voirs. Hospital staff along with hospital settings are also playing
their part to a greater extent [28].
6. Selected antibiotic-resistant nosocomial pathogens
Multi-drug-resistant nosocomial organisms include MRSA,
vancomycin-resistant enterococci, P. aeruginosa and
K. pneumonia, whereas C. difﬁcile shows natural resistance. In
the 1940s, the problem of drug resistance came into light and in
the past few years, a rapid increase of multi-drug-resistant
pathogens was seen.
Fifty to sixty percent of hospital-acquired infections are
caused by resistant pathogens in the United States. Improper use
of antibiotics is thought to be the major cause of this drug
resistance.
6.1. MRSA
b-Lactamase antibiotics including penicillin along with other
antimicrobials became resistant in the 1940s. Resistance of
penicillin slowly prevails from hospitals to community due to its
improper use. This resistance results are due to the Staphylo-
coccal species having penicillinase enzyme which was later
solved by the introduction of penicillinase-resistant antibiotics,
cephalosporins. In the 1960s, methicillin-resistant species of
S. aureus were reported. This resistance was due to the modi-
ﬁcation of penicillin-binding proteins. This modiﬁcation made
all b-lactam antibiotics along with their derivatives ineffective.
Aminoglycosides resistance was another addition to methicillin
resistance [29].
6.2. Vancomycin-resistant enterococci
Vancomycin resistance is seen in the enterococcal species
due to the vanA and vanB genes. These genes are a part of
plasmid and would spread resistance to other microbes as well.
Enterococci are resistant to different classes of antibiotics which
Hassan Ahmed Khan et al./Asian Pac J Trop Biomed 2015; 5(7): 509–514512include penicillin, ampicillin, aminoglycosides, tetracyclines,
carbapenems, ﬂuoroquinolones and macrolides [30].
6.3. P. aeruginosa
P. aeruginosa is becoming resistant due to different mecha-
nisms working against antibiotics. These mechanisms include
the restricted uptake of drug, drug modiﬁcation and altered
targets for antibiotics. Due to this increasing resistance, com-
plications are seen in the treatment of P. aeruginosa infections.
The drugs that are now ineffective due to increasing resistance
include cephalosporins, trimethoprim, macrolides, chloram-
phenicol, tetracyclines and ﬂuoroquinolones [23].
6.4. K. pneumonia
Resistance to b-lactam antibiotics is a major cause of com-
plications in nosocomial infections. K. pneumonia is one of the
microbes experiencing resistance of b-lactamase antibiotics
along with E. coli. Cephalosporins of third and fourth generation
show resistance for K. pneumonia [22].
6.5. C. difﬁcile
Increased use of broad-spectrum antibiotics against
C. difﬁcile-associated diseases makes it resistant. Cephalospo-
rins, ﬂuoroquinolones, clindamycins and ampicillins are those
antimicrobials that are usually employed for C. difﬁcile-associ-
ated diseases. Recent studies reported that the improper antibi-
otic use was the cause of increasing infections of C. difﬁcile [28].Figure 1. Measurement and comparison of infection rates.7. Control of nosocomial infections
There is a lack of actual statistics regarding the causes and
antimicrobial susceptibility in developing countries. Pathogens
with resistant organisms make it extremely difﬁcult to devise a
proper plan and its implementation for control [3].
7.1. Measurement and comparison of infection rates
It is difﬁcult to measure the infection rates in different
healthcare settings. For the measurement of infection rates, it is
important to know the types of microorganism involved and its
correct location inside the body of individual. Infectious or-
ganisms are heterogeneous in nature, which makes them
different from one another. It is possible that in a hospital, the
rates of infection show similarity while the location and het-
erogeneity of organisms greatly differ.
To compare the infection rates, one must know the type of
healthcare settings, which may be public or private, because the
infection rates vary in both types of hospitals. In addition, in
these hospitals, the management of infections differs greatly.
The types of services that a hospital provides to patients must be
taken into account (Figure 1).
7.2. Development of infection control programs
Guidelines for the sterilization and disinfection of invasive
devices and medical instruments used for surgeries were
developed as the infection rates tend to raise [31,32]. Moreover,
guidelines for the prevention of catheter-associated UTI were
Figure 2. Suggested integrated team work for surveillance of nosocomial infections in any hospital.
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guidelines, leads to the transmission of nosocomial infections.
CDC provides the methodology for surveillance of nosocomial
infections along with investigation of major outbreaks.
Infection prevention and control guidelines have been
developed but the implementation is not yet much known [34].
Training of healthcare professionals, especially nurses, is
extremely important for the control and prevention of infection
[2,35]. A large gap is present between the existence of
guidelines and their actual implementation [36].
7.3. Surveillance of nosocomial infections
Surveillance can be interpreted as “the ongoing, systematic
collection, analysis, and interpretation of health data essential to
the planning, implementation and evaluation of public health
practice, closely integrated with the timely dissemination of
these data to those who need to know” [37]. As a part of
infection control program, surveillance obliges the data related
to infected individuals with their infection sites. Hospitals can
work on this data to control the infections by evaluating the
efﬁcacy of treatment. By means of this surveillance(Figure 2), hospitals can devise a strategy comprising of
infection control practices [29].
8. Conclusions
In the age of antibiotics, nosocomial infections are still un-
controllable. The control of organisms responsible for nosoco-
mial infections is much needed as they cause great economic as
well as production loss. The transmission of these infections in
the hospital settings through healthcare workers can be avoided
by the use of infection control practices. Improper and frequent
use of antibiotics is an important cause of drug-resistant or-
ganisms that are difﬁcult to treat. Hospitals should devise the
infection control programs through which infection rates can be
compared and controlled. A well-managed surveillance meth-
odology is required in the light of CDC guidelines. In addition,
there is also great need that the best practice should be shared
among hospitals to stop the spread of nosocomial infections.
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